Press release
Lizhuo Pharmaceutical Technology: Empagliflozin Intermediate 3 CAS NO. 1279691-36-9
Image: https://www.abnewswire.com/upload/2025/02/244d490e8e67be1fc6fd489f30405e07.jpg
CAS NO.:1279691-36-9
Synonyms:
Empagliflozin N-1;
(2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol;
Methyl 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]Methyl]phenyl]-alpha-D-glucopyranoside;
Related Categories:Empagliflozin intermediates; pharmaceutical raw materials; pharmaceutical intermediates; organic intermediates.
Appearance: White to Off-White solid
Purity: 98%
Application: Empagliflozin intermediates;pharmaceutical intermediate
Supply Ability
Empagliflozin Intermediate3 CAS NO.1279691-36-9 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally
If you are interested in Empagliflozin Intermediate3 CAS NO.1279691-36-9, feel freely contact us please, and we will provide you the best quality products, reasonable price and best service, expecting to our cooperation.
Company Profile
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. is a subsidiary of Shenzhen Rich Chemical Technology Co., Ltd., located in Shanghai. Since its establishment, Lizhuo Pharmaceutical has been committed to providing global pharmaceutical companies and new drug research and development institutions with comprehensive solutions from early product development to drug listing. R&D, customization and production services of pharmaceutical intermediates and APIs required in the life cycle.
Lizhuo Pharmaceutical is a comprehensive technology enterprise focusing on the R&D, production and sales of pharmaceutical intermediates, mainly developing and producing anti-tumor, psychotropic, antiviral, hypoglycemic and antibacterial pharmaceutical intermediates. Our company also engaged in developing innovative drug intermediates according to the situation of the new drug market, and at the same time, develop and customize new drug intermediates according to the needs of customers.
Company Culture [https://www.shlzpharma.com/about-us/]
Lizhuo Pharmaceutical has always adhered to the principle of "keeping promises and honoring promises" and the business philosophy of "excellence, continuous improvement, innovation and development, openness and sharing", striving to provide professional and fast technology and production services, and striving to be a first-class pharmaceutical intermediate and API companies.
Our company has a complete R&D, pilot and scale-up production base. Currently, we have one 1,000-square-meter R&D laboratory, 2 pilot production workshops in Wuhan, equipped with twenty 50L-1000L reactors, high and low temperature Circulation device (-40 degrees C-200 degrees C), ultra-low temperature reaction device (-120 degrees C), vacuum and atmospheric distillation tower (2-6 meters), molecular distillation, solid distillation and other advanced equipment, can undertake ultra-low temperature reaction, format Continuous reaction, nitration reaction, nitro reduction reaction, epoxidation synthesis reaction, solid-liquid distillation and rectification and other production processes, the research and development center can undertake the customization of pharmaceutical intermediates from grams to kilograms, and the pilot production workshop and factory can Produce hundreds of kilograms to tons of products.
The researchers of Lizhuo Pharmaceutical are all doctoral and master technicians who have been engaged in the pharmaceutical synthesis business for many years. They have certain research and achievements in the technical field, and they also have rich practical experience in engineering amplification. At the same time, we also cooperate with Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, School of Pharmacy, Zhejiang University, School of Pharmacy, Zhejiang University of Technology and other institutions to develop projects, so as to promote the research and development of new drugs faster and better, and have achieved a number of research results.
Media Contact
Company Name: Shanghai Lizhuo Pharmaceutical Technology Co.,Ltd.
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lizhuo-pharmaceutical-technology-empagliflozin-intermediate-3-cas-no-1279691369]
Country: China
Website: https://www.shlzpharma.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lizhuo Pharmaceutical Technology: Empagliflozin Intermediate 3 CAS NO. 1279691-36-9 here
News-ID: 3872066 • Views: …
More Releases from ABNewswire
Exploring the Impact of U.S. Government Shutdown on the Global Markets - An Excl …
Image: https://www.abnewswire.com/upload/2025/11/6ab92174e3dc0ee6c1bfafc8e655cfb4.jpg
A shutdown of the U.S. federal government, when Congress fails to pass spending legislation and many agencies cease non-essential operations, poses a material risk to the economy. But when viewed through the lens of market history and global asset flows, the evidence suggests that such shutdowns are often absorbed by the markets and, in several ways, may present tactical opportunities for globally diversified investors.
1. What a U.S. Government Shutdown…
Green Ammonia Market size growing at CAGR of 82.47% by 2030 | Rising Fertilizer …
The latest research by Mordor Intelligence covers the "Green Ammonia Market," delivering insights into market dynamics, drivers of growth, and long-term forecasts.
Green Ammonia Market Overview:
The global green ammonia market is expanding steadily as countries accelerate the shift toward low-carbon fertilizer, marine fuel, power generation, and hydrogen transport solutions. The green ammonia market [https://www.mordorintelligence.com/industry-reports/green-ammonia-market?utm_source=abnewswire] size is expected to grow from 0.27 million tons in 2025 to 5.41 million tons by 2030,…
Point of Care Diagnostics Market to Reach USD 84.93 Billion by 2030, Driven by R …
Mordor Intelligence has published a new report on Point Of Care Diagnostics Market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
The Point Of Care Diagnostics Market [https://www.mordorintelligence.com/industry-reports/point-of-care-diagnostics?utm_source=abnewswire] size is estimated at USD 53.63 billion in 2025, and is expected to reach USD 84.93 billion by 2030, at a CAGR of 9.63% during the forecast period (2025-2030). The market's growth is fueled by the increasing need for rapid,…
Enteral Feeding Devices Market Forecast to Reach USD 4.94 Billion by 2030, Drive …
Mordor Intelligence has published a new report on enteral feeding devices market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
The enteral feeding devices market [https://www.mordorintelligence.com/industry-reports/enteral-feeding-devices-market?utm_source=abnewswire] is projected to grow from approximately USD 3.72 billion in 2025 to USD 4.94 billion by 2030, according to a recent report by Mordor Intelligence. The growth reflects a compound annual growth rate (CAGR) of around 5.84 percent, driven primarily by technological…
More Releases for Empagliflozin
Global Empagliflozin, Dapagliflozin And Canagliflozin Market Outlook 2025-2034: …
The Empagliflozin, Dapagliflozin And Canagliflozin Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Empagliflozin, Dapagliflozin And Canagliflozin Market Size and Projected Growth Rate?
The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.64 billion in…
Empagliflozin Impurity Standards: Ensuring Uncompromised Drug Quality with Preci …
Empagliflozin, a widely prescribed medication for managing Type 2 diabetes, has revolutionized the approach to treatment by enabling better glycemic control and reducing cardiovascular risks. As its demand grows, so does the need for impeccable quality standards to ensure its efficacy and safety for patients worldwide. Integral to achieving this is the availability of well-characterized impurity standards, which form the cornerstone for rigorous quality testing.
To meet these precise requirements, Empagliflozin…
Empagliflozin, Dapagliflozin And Canagliflozin Market Report By Size, Share And …
The Business Research Company recently released a comprehensive report on the Global Empagliflozin, Dapagliflozin And Canagliflozin Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Empagliflozin, Dapagliflozin And Canagliflozin Market Size, Share Analysis And T …
The new report published by The Business Research Company, titled Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from…
Empagliflozin, Dapagliflozin and Canagliflozin Market Research Report 2023: …
Empagliflozin, Dapagliflozin and Canagliflozin are three main types of SGLT-2 inhibitors.
Global Empagliflozin, Dapagliflozin and Canagliflozin Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the…
Empagliflozin Tablets Market Opportunities and Growth Challenges Report 2022-203 …
Global Empagliflozin Tablets Market 2022-2028 - Global Industry Size, Supply Analysis, Price Analysis, Consumption and Production, Supplier and Cost Structure Analysis
Empagliflozin Tablets Market Overview
The recent market intelligence study by the research analysts at Market Business Insights (MBI) takes a deep dive into inner operations of the global Empagliflozin Tablets Market. It thoroughly examines the market landscape to give the readers an accurate insight into the current, as well as the…
